- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repligen Corporation (RGEN)
Track today's live Repligen (RGEN) share price, performance and key data on this page with our current NASDAQ:RGEN stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Repligen share price on the NASDAQ exchange. Use the dropdown to switch exchange for the RGEN share price, head to our technical summary section, which provides analysis on Repligen share price buy/sell indicators using real-time data (or discuss the Repligen (RGEN) stock price today with other investors in the Repligen NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RGEN share price (ISIN: US7599161095) to enhance your trading decisions with our free investment tools and resources.
What Is the Repligen Corporation Share Price Today?
The Repligen share price today is 167.79.
What Is the Stock Symbol for Repligen Corporation
The stock symbol (or 'ticker') for Repligen Corporation is "RGEN."
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:RGEN share price (ISIN: US7599161095) to enhance your trading decisions with our free investment tools and resources.
What Is the Repligen Corporation Share Price Today?
The Repligen share price today is 167.79.
What Is the Stock Symbol for Repligen Corporation
The stock symbol (or 'ticker') for Repligen Corporation is "RGEN."
What Stock Exchange Does Repligen Corporation Trade On?
Repligen Corporation is listed and trades on the NASDAQ stock exchange.
Is Repligen Corporation a Good Stock to Buy?
Determining whether Repligen (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
165.26
169.04
52 wk Range
100.99
198.87
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
165.26169.04
52 wk Range
100.99198.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
203.21
Upside
+21.11%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
15 analysts have revised their earnings downwards for the upcoming period
Repligen Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 8K Repligen Corporation For: 30 October
- Investing.com
- Form 8K Repligen Corporation For: 30 October
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell
Analyst Ratings
16 Buy
4 Hold
0 Sell
Ratings:
20 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 203.21
(+21.11% Upside)
Repligen Corporation SWOT Analysis
Bioprocessing Pionee | Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth |
Financial Resilience | Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025 |
Market Dominance | Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership |
Future Trajectory | Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion |
Repligen Corporation Earnings Call Summary for Q3/2026
- Repligen posted Q3 2026 revenue of $209M (up 11% YoY) and adjusted EPS of $0.53, beating estimates of $206.7M and $0.46 per share respectively.
- Organic revenue growth hit record 12.5%; Chromatography rose 50%+, Proteins 40%+, Analytics 20%, while Filtration declined 11% amid customer headwinds.
- Company raised FY2026 guidance to $844M-$852M revenue with 12-13% organic growth; expects to exceed $1B revenue in 2027 for the first time.
- BioLife acquisition closed in October, expected to add $24M in 2026 revenue and be at least $0.05 accretive to 2027 earnings with integration underway.
- Shares fell 2.25% to $176.12 despite earnings beat as investors weighed timing delays in equipment revenue and near-term filtration weakness against outlook.
Last Updated: 27/10/2026, 13:14
Read Full TranscriptEarnings
Latest Release
27/10/2026
EPS / Forecast
0.53 / 0.46
Revenue / Forecast
209M / 206.7M
Compare RGEN to Peers and Sector
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −908.7x | −0.4x | −0.2x | |
PEG Ratio | 0.99 | 0.08 | 0.00 | |
Price/Book | 5.1x | 5.7x | 2.6x | |
Price / LTM Sales | 13.3x | 3.6x | 2.8x | |
Upside (Analyst Target) | 21.1% | 15.7% | 65.0% | |
Fair Value Upside | Unlock | 3.1% | 9.6% | Unlock |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Repligen (NASDAQ: RGEN) Share Price Today?
The Repligen stock price today is 167.79 USD.
What Stock Exchange Does Repligen (RGEN) Trade On?
Repligen is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Repligen?
The stock symbol (also called a 'ticker') for Repligen is "RGEN."
What Is the Current Repligen Market Capitalisation?
As of today, Repligen (NASDAQ: RGEN) market cap is 10.64B USD.
What Is Repligen's (RGEN) Earnings Per Share (TTM)?
The Repligen EPS is currently -0.21 (Trailing Twelve Months).
When Is the Next Repligen Earnings Date?
Repligen's next earnings report will be released on 24/02/2027.
Is RGEN a Buy or Sell From a Technical Analyst Perspective?
Based on today's Repligen moving averages and other technical indicators, the daily buy/sell signal for RGEN stock is Strong Sell.
How Many Times Has Repligen Stock Split?
Repligen has split 0 times. (See the RGEN stock split history page for full effective split date and price information.)
How Many Employees Does Repligen Have?
Repligen has 2000 employees, based on their latest Companies House report.
What is the current trading status of Repligen (NASDAQ: RGEN)?
As of 14/11/2026, Repligen (RGEN) is trading at a share price of 167.79 USD, with a previous close of 166.52 USD. The stock has fluctuated within a day range of 165.26 USD to 169.04 USD, while its 52-week range spans from 100.99 USD to 198.87 USD.
What Is Repligen (RGEN) Price Target According to Analysts?
The average 12-month price target for Repligen is 203.21 USD, with a high estimate of 235 USD and a low estimate of 175 USD. 16 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21.11% Upside potential.
What Is the RGEN Premarket Price?
RGEN's last pre-market stock price is 168.50 USD. The pre-market share volume is 10,690.00, and the stock has decreased by 1.98, or 1.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.